Literature DB >> 30679078

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.

Anand Narayanan1, Friedrich D Knollmann2, Julie Ann S Walby3, Steffany Lim4, David R Gandara4, Jonathan W Riess5.   

Abstract

Entities:  

Keywords:  Atezolizumab; EBV-positive malignancy; Immunotherapy; PD-L1 antibody; Pulmonary lymphoepithelioma-like carcinoma

Mesh：

Substances：

Year:  2018        PMID： 30679078     DOI： 10.1016/j.cllc.2018.12.015

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  10 in total

1.  Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.

Authors:  Hejing Bao; Ling Zhen Ma; Chengzhu Zhao; Mengge Yu; Baishen Zhang; Juan Zhang; Guibao Peng; Xiaotong Lin; Yinhua Fang; Hehong Bao; Shudong Ma
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-04       Impact factor: 4.553

2.  High PD-L1 level of advanced hepatic lymphoepithelioma-like carcinoma response favorably to lenvatinib plus toripalimab.

Authors:  Yueting Zhu; Zhuyi Dang; Hang Xu; Yunlong Yuan; Ye Chen; Zhiping Li
Journal:  Cancer Sci       Date:  2022-03-24       Impact factor: 6.518

3.  Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report.

Authors:  Zhi-Xin Qiu; Ping Zhou; Ke Wang
Journal:  Onco Targets Ther       Date:  2019-10-17       Impact factor: 4.147

4.  Primary pulmonary lymphoepithelioma-like carcinoma: A case report of pathological complete response (pCR) by neoadjuvant treatment.

Authors:  Liqin Zhang; Tairan Hao; Yuqing Wei; Mo Dong; Yuancheng Xiong
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

5.  Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma： A Retrospective Study.

Authors:  Yi Xiao; Jinyuan He; Shaoning Luo; Min Dong; Wei Li; Gaijiao Liu; Hongjie Chen; Xiongwen Yang; Shaohong Huang
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

6.  PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.

Authors:  Xuanye Zhang; Yixin Zhou; Hualin Chen; Chen Chen; Zuan Lin; Li-Na He; Wei Du; Tao Chen; Shaodong Hong; Sha Fu
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

7.  PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Yu-Min Zhong; Kai Yin; Yu Chen; Zhi Xie; Zhi-Yi Lv; Jin-Ji Yang; Xue-Ning Yang; Qing Zhou; Bin-Chao Wang; Wen-Zhao Zhong; Ling-Ling Gao; Wen-Bin Zhou; Ji Chen; Hai-Yan Tu; Ri-Qiang Liao; Dong-Kun Zhang; Shui-Lian Zhang; Dan-Xia Lu; Hong-Bo Zheng; Heng-Hui Zhang; Yi-Long Wu; Xu-Chao Zhang
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

8.  Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience.

Authors:  Yang Fu; Yue Zheng; Pei-Pei Wang; Yue-Yun Chen; Zhen-Yu Ding
Journal:  Onco Targets Ther       Date:  2021-02-16       Impact factor: 4.147

9.  Surgical treatment of Epstein-Barr virus-associated lymphoepithelioma-like carcinoma occurring in both the posterior mediastinum and liver: Case report.

Authors:  Xiao-Hui Qian; Dong-Kai Zhou; Wei-Lin Wang
Journal:  Medicine (Baltimore)       Date:  2020-12-24       Impact factor: 1.817

Review 10.  The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers.

Authors:  Alison Felipe Bordini Biggi; Deilson Elgui de Oliveira
Journal:  Biomolecules       Date:  2022-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.